KT
Kasvu Therapeutics
Finland · Biotech · Healthtech
Kasvu Therapeutics develops small-molecule treatments intended to stimulate neuroplasticity without the hallucinogenic effects associated with psychedelic drugs.
Drug design around the TrkB pathway
Kasvu uses a proprietary three-dimensional computational model to design positive allosteric modulators of the TrkB receptor. The molecules are intended to amplify the body’s BDNF signalling while avoiding activation of the 5-HT2A receptor associated with hallucinations.
Its lead candidate, KTX-0141, is in studies preparing for clinical development. The initial clinical programme is aimed at major depressive disorder, within a broader focus on neuropsychiatric and neurodegenerative conditions.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | €30M | Hadean Ventures — LeadFinnish Drug Discovery Center — ParticipantHelsinki University Funds — ParticipantInnovestor Life Science Fund — ParticipantNordic Science Investments — ParticipantStephen Industries — ParticipantTesi — Participant |